Nuclear Medicine/Radiopharmaceuticals Global Market –
Forecast To 2030
Bharat Book Bureau Provides the Trending Industry Research Report on“Nuclear
Medicine/Radiopharmaceuticals Global Market – Forecast To 2030”under Life Sciences
Market Research Report. The report offers a collection of superior Market research, Market
analysis, competitive intelligence and Market reports.
Over the past 50 years, the Nuclear Medicine field has displayed a strong link between
investments in chemistry and the development of radionuclide and radio-labeled compounds
which have impacted the healthcare practice. Nuclear medicine comprises diagnostic and
therapeutic techniques that use radioisotopes for applications like oncology, cardiovascular and
neurological disorders to provide information at both molecular and cellular levels for probing,
tracking tissue function, study disease progression and assessing treatment responses.
The nuclear medicine global market is poised to grow at a high single digit CAGR from 2020 to
2027 to reach $10,742.7 million by 2027. Increasing radioisotopes applications, rise in public
awareness, use of SPECT/CT and PET/CT imaging scans, the abundance of
radiopharmaceuticals, advancement in imaging technology (hybrid imaging) and alpha therapy
based targeted cancer treatment is boosting nuclear medicine market growth. In addition,
increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons,
efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional
equipment are the opportunities likely to propel the growth of the nuclear medicine market.
The nuclear medicinal market is classified based on modality into diagnosis and therapeutics.
The diagnostics market commanded the largest market revenue in 2020 and is expected to grow
at a mid single digit CAGR from 2020 to 2027 due to an increase in SPECT and PET
procedures. The therapeutics segment is projected to grow at high teen CAGR from 2020 to 2027